2023-506108-23-00CompletedPhase 1
A trial to learn how baxdrostat affects the heartbeat in healthy participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Apr 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- First submitted
- 8 Nov 2023
- Start date
- 6 Feb 2024
- Lead sponsor
- Astrazeneca AB
- EU CT number
- 2023-506108-23-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 28
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Parexel International GmbH | Berlin | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.